Current Challenges in the Treatment of Invasive Aspergillosis in Geriatric Patients

Current Challenges in the Treatment of Invasive Aspergillosis in Geriatric Patients

<b>Background:</b> Invasive aspergillosis (IA) is a severe fungal infection increasingly affecting elderly patients with chronic respiratory diseases and prolonged corticosteroid use. <b>Methods:</b> We evaluated clinical, biochemical, and fungal biomarkers in 45 patients ove...

Full description

Saved in:
Bibliographic Details
Main Authors: Sara Fueyo Álvarez, Elena Valle Calonge, Julieth Andrea Caballero Velasquez, Alba Magaly Revelo Rueda, Pablo Enrique Solla Suarez, Eva María López Álvarez, Mercedes Rodriguez Perez, María Teresa Peláez García de la Rasilla
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Journal of Fungi
Subjects:
invasive aspergillosis
geriatrics
mortality
Online Access:https://www.mdpi.com/2309-608X/11/7/480
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<b>Background:</b> Invasive aspergillosis (IA) is a severe fungal infection increasingly affecting elderly patients with chronic respiratory diseases and prolonged corticosteroid use. <b>Methods:</b> We evaluated clinical, biochemical, and fungal biomarkers in 45 patients over 80 years diagnosed with IA and hospitalized in a Spanish Acute Geriatric Unit. Patients received either voriconazole or isavuconazole. Mortality rates and associated risk factors were analyzed. <b>Results:</b> Overall mortality was 35.61%. Significant mortality risk factors included leukocytosis (<i>p</i> = 0.0371), neutrophilia (<i>p</i> = 0.0144), and lymphopenia (<i>p</i> = 0.0274). Deceased patients had longer hospital stays (26.6 vs. 16.8 days; <i>p</i> = 0.00353). Voriconazole treatment was associated with higher 30-day mortality (61.5% vs. 19.2%; <i>p</i> = 0.0001) and a higher incidence of adverse effects (60% vs. 5%; <i>p</i> = 0.0003) compared to isavuconazole. Voriconazole also showed greater pharmacokinetic variability, with 76.9% of cases outside the therapeutic range. <b>Conclusions:</b> Voriconazole may not be optimal for IA treatment in patients over 80 years. Isavuconazole demonstrated a more favorable safety and efficacy profile. Personalized therapeutic strategies and a multidisciplinary approach are essential to improve clinical outcomes and quality of life in this vulnerable population.
ISSN:2309-608X

Similar Items